US drug industry group launches campaign to defend pricingBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4902 (Published 09 September 2016) Cite this as: BMJ 2016;354:i4902
- Michael McCarthy
A major drug industry group in the United States has launched a media campaign to defend pricing policies in the face of growing demand for government action to control the soaring prices of generic and brand name prescription drugs.1 2
Over the past year reports of steep price rises of many commonly used drugs such as insulin, rises of as much as 5000% for some off-patent generic drugs, and the introduction of new specialty drugs that can cost more than $100 000 (£75 000; €90 000) for a course of treatment have led to Congressional investigations and calls for legislation to curtail drug costs.
US residents pay the most in the world …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.